Financial Performance - In 2025, the total operating revenue reached RMB 342.94 million, a year-on-year increase of 1.95%[5] - The net profit attributable to shareholders of the parent company was RMB 52.26 million, a decrease of 47.04% compared to the previous year[5] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 41.37 million, down 42.30% year-on-year[5] - The basic earnings per share decreased by 41.62% to RMB 1.15[3] Assets and Equity - The company's total assets at the end of the reporting period were RMB 1,898.69 million, a decrease of 1.41% from the beginning of the period[3] - The equity attributable to shareholders of the parent company was RMB 1,728.26 million, down 2.08% from the beginning of the period[3] Research and Development - The company increased its R&D investment by 5.14% to maintain product advancement and accelerate technology iteration[6] Expenses and Costs - Management expenses increased by 68% due to the new park's operational and amortization costs[6] - The decline in the factory price of the disposable breast biopsy needle due to centralized procurement led to a decrease in gross profit by RMB 22.02 million[7] Financial Income - Financial income decreased by 63% due to a decline in investment yield[6]
西山科技(688576) - 2025 Q4 - 年度业绩